Although a German court ruled to set aside a €142 million ($161.8 million) arbitral award issued to Austrian pharmaceutical company AOP Orphan last month, the Austrian company and the Taiwanese drug developer who would have had to pay it have differing opinions on where their Massachusetts federal court dispute should go from here.